'recombinant vaccine' — Téarmaíocht / Téarmaíocht IATE | Grúpa taighde Gaois

Léim go príomhábhar an leathanaigh

5 thoradh

SOCIAL QUESTIONS|health|pharmaceutical industry · SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine · PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology

#634590
IATE #1686508

vacsaín athchuingreach Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

rekombinanter Impfstoff | Impfstoff auf der Grundlage rekombinierender DNA
de

recombinant vaccine
en

Sainmhíniú vaccine developed using recombinant technologies Tagairt "COM-Terminology Coordination, based on: Yadav T, Srivastava N, Mishra G, et al., 'Recombinant vaccines for COVID-19' (9.3.2021), Human Vaccines & Immunotherapeutics 2020;16(12):2905-2912, doi:10.1080/21645515.2020.1820808"
vaccin recombinant | vaccin basé sur la recombinaison d'ADN
fr

Sainmhíniú vaccin obtenu par génie génétique Tagairt "Vidal EurekaSanté. Lexique médical. Vaccin http://www.eurekasante.fr/lexique-medical/V.html [20.9.2011]"
SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine · SOCIAL QUESTIONS|health|pharmaceutical industry · PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology

#685622
IATE #3590043

vacsaín veicteora víreasaigh Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

viraler Vektorimpfstoff
de

viral vector vaccine | viral vector-based vaccine | live recombinant viral vectored vaccine | virus vector vaccine | virus vector vaccines
en

Sainmhíniú vaccine consisting of a live virus (the vector) that expresses a heterologous antigen(s) Tagairt "COM-Terminology Coordination: European Medicines Agency. Committee for Medicinal Product for Human Use (CHMP) 'Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines' (9.3.2021). 24 June 2010 EMA/CHMP/VWP/141697/2009"
Nóta Heterologous vector: When the target species of the vaccine is not one of the natural hosts for the vector, the vector is classified as a heterologous vector.
vaccin à vecteur viral | vaccin à base de vecteur viral | vaccin vectoriel
fr

Sainmhíniú "vaccin qui consiste à combiner le virus à combattre avec un autre virus atténué ou inoffensif utilisé comme véhicule (vecteur viral), permettant de délivrer les antigènes directement dans les compartiments du système immunitaire susceptibles d’induire une réponse mémoire protectrice" Tagairt "COM-FR, d'après:- MSN Actualité, Article issu du Journal Le Soir (29 avril 2020), Vaccins anti-covid: une équation à plusieurs inconnues (1.7.2020)- Institut Pasteur, Communiqué de presse du 19 mars 2020 > Covid-19 : le CEPI finance le développement d’un vaccin contre SARS-CoV-2, projet porté par le consortium de l’Institut Pasteur, de Themis et de l’université de Pittsburgh (1.7.2020)"
SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

#642983
IATE #3510246

vacsaín beoveicteora athchuingreach Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

rekombinanter Lebendimpfstoff
de

recombinant live vector vaccine
en

Sainmhíniú preparations of one or more types of live bacteria or viruses into which one or more DNA/RNA sequences have been inserted Tagairt "COM-Terminology Coordination, based on: European Medicines Agency (EMA). COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP). 'GUIDELINE ON LIVE RECOMBINANT VECTOR VACCINES FOR VETERINARY USE' (9.3.2021). EMEA/CVMP/004/04-FINAL"
Nóta Recombinant live vector vaccines are expected to be attenuated and genetically defined live vaccines, which have defined, non-reverting mutations or deletions.
vaccin vivant à vecteur recombinant | vaccin vivant recombinant
fr
SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

#664943
IATE #3593154

vacsaín phróitéine athchuingreach Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

vacsaín fo-aonaid phróitéine athchuingreach Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

recombinant protein subunit vaccine | recombinant protein vaccine | recombinant subunit | recombinant protein-based vaccine
en

Sainmhíniú "type of protein subunit vaccine that is formulated using defined protein antigens that can be produced in heterologous expression systems" Tagairt "COM-Terminology Coordination, based on: Wang M, Jiang S, Wang Y. 'Recent advances in the production of recombinant subunit vaccines in Pichia pastoris' (9.3.2021). Bioengineered. 2016;7(3):155-165. doi:10.1080/21655979.2016.1191707"
SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

#665658
IATE #3599598

vacsaín nanacháithníní spícephróitéine athchuingreach SARS-CoV-2 Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex

ga

SARS-CoV-2 recombinant spike protein nanoparticle vaccine
en

Sainmhíniú recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant Tagairt "Cheryl Keech, M.D., Ph.D., Gary Albert, M.S., Iksung Cho, M.S., Andreana Robertson, M.S., Patricia Reed, B.S., Susan Neal, Joyce S. Plested, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark, B.S., Haixia Zhou, Ph.D., Gale Smith, Ph.D., Nita Patel, M.S., Matthew B. Frieman, Ph.D., Robert E. Haupt, M.S., James Logue, B.A., Marisa McGrath, B.A., Stuart Weston, Ph.D., Pedro A. Piedra, M.D., Chinar Desai, B.S., Kathleen Callahan, M.S., Maggie Lewis, M.S., Patricia Price-Abbott, M.S., Neil Formica, M.B., B.S., Vivek Shinde, M.D., Louis Fries, M.D., Jason D. Lickliter, M.B., B.S., Ph.D., Paul Griffin, M.D., Bethanie Wilkinson, Ph.D., and Gregory M. Glenn, M.D., 'Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine' (18.6.2021), New England Journal of Medicine 2020; 383:2320-2332"
NVX-CoV2373
mul